Editorial: Innate lymphoid cells in cancer: volume II - Takeaways - MDSpire

Editorial: Innate lymphoid cells in cancer: volume II

  • By

  • Nicolas Jacquelot

  • Emilie Narni-Mancinelli

  • Alexander David Barrow

  • June 15, 2026

  • 0 min

Share

  • 1

    The second volume on Innate Lymphoid Cells (ILCs) highlights their role as active modulators in cancer progression and therapeutic outcomes.

  • 2

    ILCs consist of five subsets that function independently of antigen-specific receptors, influencing tissue homeostasis and inflammation.

  • 3

    Research in this volume explores ILC interactions with the tumor microenvironment and their responses to immunotherapeutic interventions.

  • 4

    Innovative techniques, such as a 25-parameter spectral flow cytometry panel, enhance the characterization of ILC subsets in tumors.

  • 5

    The integration of ILC biology into cancer immunotherapy is poised to advance the development of targeted therapeutic strategies.

Original Source(s)

Editorial: Innate lymphoid cells in cancer: volume II

  • by Nicolas Jacquelot, Emilie Narni-Mancinelli, Alexander David Barrow

  • June 15, 2026

Related Content

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy

Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer

Conditional survival analysis May enhance prognosis estimate in buccal mucosa carcinoma